Testing effectiveness (Phase 2)Study completedNCT02354690What this trial is testingVemurafenib and TIL Therapy for Metastatic MelanomaWho this might be right forMetastatic Melanoma Inge Marie Svane 13
Early research (Phase 1)Ended earlyNCT01876641What this trial is testingTreatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus CobimetinibWho this might be right forMetastatic MelanomaMelanomaBRAF-mutated Metastatic Melanoma+1 more Mohammed M Milhem 18
Early research (Phase 1)Looking for participantsNCT04913285What this trial is testingEvaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid TumorsWho this might be right forSolid Tumor, AdultNon-small Cell Lung CancerMelanoma Pierre Fabre Medicament 400
Testing effectiveness (Phase 2)Ended earlyNCT01978236What this trial is testingDabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and MetabolitesWho this might be right forMelanoma and Brain Metastases GlaxoSmithKline 6
Testing effectiveness (Phase 2)Ended earlyNCT01551693What this trial is testingSTA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV MelanomaWho this might be right forMelanoma Dana-Farber Cancer Institute 3
Early research (Phase 1)Study completedNCT02027961What this trial is testingPhase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib AloneWho this might be right forMelanoma MedImmune LLC 68
Testing effectiveness (Phase 2)UnknownNCT02202200What this trial is testingPhase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic MelanomaWho this might be right forMelanoma BRAF V600E/K MutatedCDNKN2A Loss Defined Assistance Publique - Hôpitaux de Paris 40
Testing effectiveness (Phase 2)Study completedNCT00866177What this trial is testingMEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV MelanomaWho this might be right forRecurrent MelanomaStage III Skin MelanomaStage IV Skin Melanoma National Cancer Institute (NCI) 167
Large-scale testing (Phase 3)Ended earlyNCT02967692What this trial is testingThe Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced MelanomaWho this might be right forMelanoma Novartis Pharmaceuticals 568
Large-scale testing (Phase 3)Active Not RecruitingNCT04657991What this trial is testingA Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic MelanomaWho this might be right forMelanoma Pfizer 257
Early research (Phase 1)WithdrawnNCT04759846What this trial is testingHepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF MelanomaWho this might be right forBRAF V600 MutationUnresectable MelanomaMetastatic Melanoma+1 more Pierre Fabre Medicament
Early research (Phase 1)Study completedNCT01767454What this trial is testingStudy of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable MelanomaWho this might be right forSolid Tumours GlaxoSmithKline 38
Testing effectiveness (Phase 2)UnknownNCT03514901What this trial is testingTo Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.Who this might be right forMelanoma MetastaticBRAF V600 Mutation Intergruppo Melanoma Italiano 120
Testing effectiveness (Phase 2)Ended earlyNCT01942993What this trial is testingThe Effects of Treatment With Vemurafenib on the Immune System in Advanced MelanomaWho this might be right forMelanoma Philip Friedlander 3
Early research (Phase 1)Study completedNCT02608034What this trial is testingInvestigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady StateWho this might be right forMetastatic Melanoma, BRAF V600 Mutation Positive Genentech, Inc. 32
Very early researchLooking for participantsNCT04741997What this trial is testingAdjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in MelanomaWho this might be right forMelanoma Stage IIIMelanoma Stage IVBRAF V600 Mutation H. Lee Moffitt Cancer Center and Research Institute 50
Testing effectiveness (Phase 2)Ended earlyNCT05926960What this trial is testingA Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced MelanomaWho this might be right forMelanoma Pfizer 38
Early research (Phase 1)Ended earlyNCT01400451What this trial is testingPh I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)Who this might be right forMelanoma Bristol-Myers Squibb 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT04557956What this trial is testingTesting the Addition of the Anti-cancer Drug, Tazemetostat, to (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual TreatmentWho this might be right forClinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Melanoma National Cancer Institute (NCI) 16
Not applicableActive Not RecruitingNCT07022457What this trial is testingUK ENcorafenib and BInimetinib Real-world Study in MelanomaWho this might be right forMetastatic Melanoma, BRAF V600 Mutation Positive Pierre Fabre Ltd 50